PBPK Modeling & Simulation

Application of Physiologically-based Pharmacokinetic Model to Predict Tramadol Concentration in Human Milk

0 comments. Click here to read/write comments.

Topics:

Prediction of the Pharmacokinetics of Renally-excreted Antiretrovirals in Older Patients, Using Physiologically-based Pharmacokinetic (PBPK) Modeling

0 comments. Click here to read/write comments.

Topics:

Physiologically-based Pharmacokinetic Model (PBPK) for the Halofantrine Cardiac Effect Prediction – Proof of Concept Study towards the System for the Antimalarial Drugs Cardiac Safety Assessment

0 comments. Click here to read/write comments.

Topics:

Sensitivity Analysis of P-glycoprotein Ki Values in Dynamic DDI Predictions

0 comments. Click here to read/write comments.

Topics:

Statistical Power Analysis to Detect Drug-drug Interaction between Lorezapam and Probenecid in Healthy and Renal-impaired Populations Using PBPK Modeling and the Simcyp R Package

0 comments. Click here to read/write comments.

Topics:

Predicting Human Fetal Exposure using Physiologically-based Pharmacokinetic Models

0 comments. Click here to read/write comments.

Topics:

Application of Global Sensitivity Analysis Methods to Determine the Most Influential Parameters of a Minimal PBPK Model of Quinidine

0 comments. Click here to read/write comments.

Topics:

Certara Launches CODEx to Inform Comparative Effectiveness and Drug Development Decisions

PRINCETON, NJ – June 6, 2017 – Certara today launched its Clinical Outcomes Database Explorer (CODEx). An intuitive, web-based platform, CODEx enables drug development teams to easily visualize, explore, analyze and communicate content from Certara’s Clinical Trial Outcomes Databases and assess a given compound’s probability of success against competitor drugs.

0 comments. Click here to read/write comments.

Topics:

A Whole Body Physiologically-based Pharmacokinetic Model for Antibody Drug Conjugates – Model Development and Validation in Rat

0 comments. Click here to read/write comments.

Topics:

Certara Partners with PUMC Hospital to Deliver Support for Chinese Drug Development

PRINCETON, NJ – May 31, 2017 – Certara today announced that it is partnering with Phase I Unit, Peking Union Medical College (PUMC) Hospital’s Clinical Pharmacology Research Center (PUMCH-CPRC) in Beijing to help Chinese pharmaceutical companies enhance their drug development processes.

0 comments. Click here to read/write comments.

Topics:

Simcyp Consultancy: Bespoke PBPK Modeling and Simulation

Physiologically-based Pharmacokinetic (PBPK) models describe and predict the handling of drugs by the body in a realistic way based on demography, physiology, biochemistry, and genetics. We integrate this information with in vitro drug absorption, metabolism, and transport data to simulate and predict in vivo pharmacokinetics in virtual patient populations.

0 comments. Click here to read/write comments.

Topics:

Certara Nurture

Recognizing the great importance of serving pediatrics balanced against the inherent hurdles, Certara Nurture offers comprehensive pediatric drug development services.

0 comments. Click here to read/write comments.

Topics:

Burstable Compute Grid

Certara’s Compute Grid allows you to access up to 1,800 cores in the cloud with just one click, significantly accelerating model runs. Projects that took days can now be completed in hours or even minutes, affordably and without IT support.

0 comments. Click here to read/write comments.

Topics:

PBPK Modeling and Simulation for Biologics

0 comments. Click here to read/write comments.

Topics:

Modeling & Simulation for Drug Development & Formulation

A look at how to leverage modeling and simulation technology to enhance all phases of the drug development process.

0 comments. Click here to read/write comments.

Topics:

Mechanistic Modeling of Genome Scale Molecular Interaction Networks

The scope of Physiologically-based Pharmacokinetic (PBPK) modeling can be expanded by assimilating mechanistic models of intracellular processes from the Systems Biology field. Genome Scale Metabolic Networks (GSMNs) represent whole sets of metabolic enzymes expressed in human tissues. Dynamic models of the gene regulation of key drug metabolism enzymes are also available. Here, we introduce GSMNs and review ongoing work on integrating PBPK, GSMNs and metabolic gene regulation. We demonstrate example models.

0 comments. Click here to read/write comments.

Topics:

Simcyp Access

Simcyp Access is a new cloud-based offering from the leading provider of physiologically-based pharmacokinetic (PBPK) modeling and simulation. Simcyp Access is a licensing approach that provides trained individuals at smaller pharmaceutical companies (less than 500 employees) with a method for using Certara’s Simcyp Population-based Simulator in research projects.

0 comments. Click here to read/write comments.

Topics:

Predicting Drug Exposure During Pregnancy Using PBPK Models

This webinar described how the Simcyp pregnancy-PBPK model was used to predict systemic exposure during pregnancy for two probe medications: tacrolimus and oseltamivir.

0 comments. Click here to read/write comments.

Topics:

Changing the Game in Drug Development: A Selection from Certara’s Best of Blogs

A selection of short essays from our blog containing insights from our thought leaders on how modeling and simulation has impacted and is continuing to reshape our approach to drug development.

0 comments. Click here to read/write comments.

Topics:

Using Modeling and Simulation to Combat a Global Health Priority

The Critical Path to TB Drug Regimens Initiative partnered with Certara to develop a population-based lung model that mimics drug disposition at different stages of tuberculosis infection.

0 comments. Click here to read/write comments.

Topics: